In keeping with the therapeutic effect of anti-IL-22, when administered after the onset of arthritis, IgG2a anti-collagen antibodies are significantly but modestly reduced and IgG1 and IgG2b antibodies are unaltered in mice receiving anti-IL-22. The gene discussed is IL22; the disease is arthritic joint disease.